Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 34Filgrastim 14Idarubicin 13Etoposide 12Busulfan 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Cyclophosphamide 10Mitoxantrone 8Methotrexate 7Daunorubicin 7Cyclosporine 6Tacrolimus 5Radiotherapy 5Clofarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Gemtuzumab 4Arsenic Trioxide 4Antilymphocyte Serum 4Topotecan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Decitabine 3eltrombopag 2choline magnesium trisalicylate 2aldesleukin 2Vorinostat 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Acute × Bromodeoxyuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡